Lncap: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
Line 10: Line 10:
{{reflist|2}}
{{reflist|2}}


{{SIB}}
 
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Cell lines]]
[[Category:Cell lines]]
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 17:00, 9 August 2012

WikiDoc Resources for Lncap

Articles

Most recent articles on Lncap

Most cited articles on Lncap

Review articles on Lncap

Articles on Lncap in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lncap

Images of Lncap

Photos of Lncap

Podcasts & MP3s on Lncap

Videos on Lncap

Evidence Based Medicine

Cochrane Collaboration on Lncap

Bandolier on Lncap

TRIP on Lncap

Clinical Trials

Ongoing Trials on Lncap at Clinical Trials.gov

Trial results on Lncap

Clinical Trials on Lncap at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lncap

NICE Guidance on Lncap

NHS PRODIGY Guidance

FDA on Lncap

CDC on Lncap

Books

Books on Lncap

News

Lncap in the news

Be alerted to news on Lncap

News trends on Lncap

Commentary

Blogs on Lncap

Definitions

Definitions of Lncap

Patient Resources / Community

Patient resources on Lncap

Discussion groups on Lncap

Patient Handouts on Lncap

Directions to Hospitals Treating Lncap

Risk calculators and risk factors for Lncap

Healthcare Provider Resources

Symptoms of Lncap

Causes & Risk Factors for Lncap

Diagnostic studies for Lncap

Treatment of Lncap

Continuing Medical Education (CME)

CME Programs on Lncap

International

Lncap en Espanol

Lncap en Francais

Business

Lncap in the Marketplace

Patents on Lncap

Experimental / Informatics

List of terms related to Lncap

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old caucasian male in 1977. LNCap cells are commonly used in the field of oncology. They are adherent epithelial cells growing in aggregates and as single cells.

The LNCaP cell line was established from a metastatic lesion of human prostatic adenocarcinoma. The LNCaP cells grow readily in vitro (up to 8 x 10(5) cells/sq cm; doubling time, 60 hr), form clones in semisolid media, are highly resistant to human fibroblast interferon, and show an aneuploid (modal number, 76 to 91) human male karyotype with several marker chromosomes. The malignant properties of LNCaP cells are maintained. Athymic nude mice develop tumors at the injection site (volume-doubling time, 86 hr). Functional differentiation is preserved; both cultures and tumor produce acid phosphatase. High-affinity specific androgen receptors are present in the cytosol and nuclear fractions of cells in culture and in tumors. Estrogen receptors are demonstrable in the cytosol. The model is hormonally responsive. In vitro, 5 alpha-dihydrotestosterone modulates cell growth and stimulates acid phosphatase production. The cell line does express PSA (Prostate Specific Antigen). In vivo, the frequency of tumor development and the mean time of tumor appearance are significantly different for either sex. Male mice develop tumors earlier and at a greater frequency than do females. Hormonal manipulations show that, regardless of sex, the frequency of tumor development correlates with serum androgen levels. The rate of the tumor growth, however, is independent of the gender of hormonal status of the host.

References

Template:WH Template:WS